The Institute of Cancer Research and Royal Marsden Hospital have commenced trials of Isatuximab, an immunotherapy drug that is believed to re-energise white blood cells that have been hijacked by prostate cancer into producing a protein called ‘CD38’. This protein unfortunately helps the cancer cells to develop and multiply, as it suppresses the immune system into preventing healthy white blood cells from attacking the cancer. If Isatuximab is found to be effective in countering this, the potential benefits are wide-ranging (Daily Mail 8 May 2021).